Flash Glucose Monitoring Targets in Gestational Diabetes
Key facts
- Who runs it
- University Medical Centre Ljubljana
- Where
- Slovenia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 205 people enrolled
- Started
- 1 Dec 2022
- Ended
- 1 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Use of FreeStyle Libre 14 day Flash Glucose Monitoring System
- Record updated
- 19 August 2025
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Pregnant women treated at the Diabetes Outpatient Clinic of the Clinical Department of Endocrinology, Diabetes, and Metabolic Diseases for gestational diabetes (GDM),
- Agreement with the study protocol and ability to follow the study protocol,
- Diagnosis of GDM established using the standard recommended OGTT method between the 24th and 28th weeks of pregnancy,
- Age between 18 and 40 years
Who cannot take part
- Treatment with systemic corticosteroids for more than 14 days prior to inclusion in the study,
- History of bariatric surgery,
- Hospitalization for psychiatric illness within the last year,
- First visit to the Diabetes Outpatient Clinic after the 34th week of gestation
- Multiple pregnancy,
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The use of glucose monitoring sensors is already well-established in pregnant women with type 1 diabetes (T1D), where it has been proven to improve glycemic control and perinatal outcomes. However, it has not yet been sufficiently researched in the area of gestational diabetes (GDM). Some smaller studies have shown a favorable effect on glycemic control, but no statistically significant differences were observed in reducing perinatal complications. A randomized, prospective study will include 200 pregnant women with GDM, treated at the Diabetes Outpatient Clinic of the Clinical Department of Endocrinology, Diabetes, and Metabolic Diseases at the University Medical Centre Ljubljana. Participants will be divided into two groups. The first group will measure subcutaneous glucose using FSL in addition to self-monitoring of blood glucose (SMBG) while fasting and 60 minutes after main meals at the same time intervals. In both groups, glycemic targets, maternal outcomes, and neonatal outcomes will be monitored. In the FSL + SMBG group, sensor parameters for glycemic control will also be tracked.
The 2 groups in the trial
- Pregnant women with GDM using FGM and SMBGTreatment being tested
Pregnant women with GDM using Flash Glucose Monitoring (FGM) and Self-Monitoring of Blood Glucose (SMBG)
Treatment: Use of FreeStyle Libre 14 day Flash Glucose Monitoring System
- Pregnant women with GDM using only SMBGExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 19 August 2025